The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversiteit Antwerpen

About this trial

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and common side effect of neurotoxic cancer treatment. The most frequent symptoms include sensory disturbances and weakness in the hands and/or feet. CIPN can interfere with both daily activities and cancer treatment itself. Although there is proof of concept for physical activity as a preventive measure for CIPN, physical activity is currently not included in the international evidence-based guideline for the prevention of CIPN due to the need of larger sample-sized definitive studies. The aim of this project is, on the one hand, to investigate the preventive effect of an exercise program based on international physical activity guidelines on CIPN symptoms in patients with breast or colorectal cancer undergoing taxane- or platinum-based chemotherapy. On the other hand, the study will also explore how patients and healthcare professionals experience the implementation of physical activity during this phase of therapy. A prospective randomized controlled trial will be conducted, with CIPN symptoms as the primary outcome measure.

Eligibility criteria

Qualifiers

age above 18 years

a primary diagnosis of breast, gynaecological or colon cancer, without distant metastasis

been chemotherapy naïve

been scheduled for at least 12 weeks of taxane- or platinum-based chemotherapy without other neurotoxic chemotherapy

Disqualifiers

life expectancy of less than six months according to the patient's oncologist or designee

advanced stage of disease

having a known current neuropathy

having cognitive or physical limitations that contraindicate participation in a low- to moderate intensity home-based walking and progressive resistance program (determined by the patient's oncologist)

Trial design

Treatments tested in this trial

  • Exercise intervention

Treatment groups

206 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Universiteit Antwerpen

Lead sponsor

University Hospital, Antwerp

Collaborator

Universitaire Ziekenhuizen KU Leuven

Collaborator

Kom Op Tegen Kanker

Collaborator